AU2019398214C1 - Fusion protein constructs for complement associated disease - Google Patents

Fusion protein constructs for complement associated disease Download PDF

Info

Publication number
AU2019398214C1
AU2019398214C1 AU2019398214A AU2019398214A AU2019398214C1 AU 2019398214 C1 AU2019398214 C1 AU 2019398214C1 AU 2019398214 A AU2019398214 A AU 2019398214A AU 2019398214 A AU2019398214 A AU 2019398214A AU 2019398214 C1 AU2019398214 C1 AU 2019398214C1
Authority
AU
Australia
Prior art keywords
seq
amino acid
acid sequence
domain
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019398214A
Other languages
English (en)
Other versions
AU2019398214B2 (en
AU2019398214A1 (en
Inventor
Justin Andrew CARAVELLA
Michael Steven Curtis
Kelly C. Fahnoe
Vernon Michael Holers
Cheng Ran Huang
Susan L. Kalled
Ellen Garber Stark
Michael Storek
Frederick Robbins Taylor
Shelia Marie Violette
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akebia Therapeutics Inc
Original Assignee
Akebia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akebia Therapeutics Inc filed Critical Akebia Therapeutics Inc
Publication of AU2019398214A1 publication Critical patent/AU2019398214A1/en
Application granted granted Critical
Publication of AU2019398214B2 publication Critical patent/AU2019398214B2/en
Priority to AU2024201109A priority Critical patent/AU2024201109A1/en
Publication of AU2019398214C1 publication Critical patent/AU2019398214C1/en
Assigned to AKEBIA THERAPEUTICS, INC. reassignment AKEBIA THERAPEUTICS, INC. Request for Assignment Assignors: Q32 BIO INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1725—Complement proteins, e.g. anaphylatoxin, C3a or C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AU2019398214A 2018-12-11 2019-12-11 Fusion protein constructs for complement associated disease Active AU2019398214C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024201109A AU2024201109A1 (en) 2018-12-11 2024-02-21 Fusion protein constructs for complement associated disease

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862778014P 2018-12-11 2018-12-11
US62/778,014 2018-12-11
PCT/US2019/065741 WO2020123662A2 (en) 2018-12-11 2019-12-11 Fusion protein constructs for complement associated disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024201109A Division AU2024201109A1 (en) 2018-12-11 2024-02-21 Fusion protein constructs for complement associated disease

Publications (3)

Publication Number Publication Date
AU2019398214A1 AU2019398214A1 (en) 2021-07-01
AU2019398214B2 AU2019398214B2 (en) 2023-11-23
AU2019398214C1 true AU2019398214C1 (en) 2024-03-28

Family

ID=71076704

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019398214A Active AU2019398214C1 (en) 2018-12-11 2019-12-11 Fusion protein constructs for complement associated disease
AU2024201109A Pending AU2024201109A1 (en) 2018-12-11 2024-02-21 Fusion protein constructs for complement associated disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024201109A Pending AU2024201109A1 (en) 2018-12-11 2024-02-21 Fusion protein constructs for complement associated disease

Country Status (13)

Country Link
US (1) US20240301043A1 (https=)
EP (1) EP3893916A4 (https=)
JP (3) JP7444886B2 (https=)
KR (2) KR102762828B1 (https=)
CN (1) CN113660944A (https=)
AU (2) AU2019398214C1 (https=)
IL (1) IL283841A (https=)
MA (1) MA54468A (https=)
MX (1) MX2021006930A (https=)
MY (1) MY209796A (https=)
PH (1) PH12021551398A1 (https=)
SG (1) SG11202106073QA (https=)
WO (1) WO2020123662A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018075783A2 (en) * 2016-10-20 2018-04-26 President And Fellows Of Harvard College In vitro and cell based assays for measuring the activity of botulinum neurotoxins
CA3141778A1 (en) * 2019-06-12 2020-12-17 CSL Innovation Pty Ltd Soluble complement receptor type 1 variant conjugates and uses thereof
AU2021293174A1 (en) 2020-06-14 2023-01-19 Vertex Pharmaceuticals Incorporated Complement Factor I-related compositions and methods
CN114778418B (zh) * 2022-06-17 2022-09-27 深圳安侣医学科技有限公司 基于显微放大数字图像的血红蛋白分析方法及系统
CN117624347A (zh) * 2022-08-30 2024-03-01 天辰生物医药(苏州)有限公司 抗人补体c5抗体以及其融合蛋白
EP4617287A1 (en) * 2022-11-10 2025-09-17 Longbio Pharma (Suzhou) Co., Ltd. Complement-inhibitory hybrid protein mutant and antibody fusion protein thereof
CN118373913B (zh) * 2024-05-08 2024-11-01 上海百英生物科技股份有限公司 一种抗人Tim-3单克隆抗体及其制备方法
CN118878672A (zh) * 2024-08-01 2024-11-01 河北康立德生物科技有限公司 一种抗曲霉半乳甘露聚糖单克隆抗体、试剂盒及其应用
CN119638823A (zh) * 2024-12-10 2025-03-18 中国医学科学院病原生物学研究所 检测a35r蛋白的单克隆抗体及其应用
CN119431565B (zh) * 2025-01-10 2025-04-08 成都迈科康生物科技有限公司 一种抗hpv16型e6蛋白和e7蛋白的抗体、检测产品及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040180046A1 (en) * 2000-04-26 2004-09-16 Jeff Himawan Bispecific molecules and uses thereof
US20130078245A1 (en) * 2010-06-22 2013-03-28 The Regents Of The University Of Colorado, A Body Corporate ANTIBODIES TO THE C3d FRAGMENT OF COMPLEMENT COMPONENT 3
WO2014028865A1 (en) * 2012-08-17 2014-02-20 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for detecting complement activation

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
MD1367C2 (ro) 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
US7708999B2 (en) * 2001-12-28 2010-05-04 Kyowa Hakko Kirin Co., Ltd. Remedies for arthritis
WO2005063815A2 (en) * 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
WO2006042252A2 (en) * 2004-10-08 2006-04-20 Potentia Pharmeceuticals, Inc. Viral complement control proteins for eye disorders
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
AU2011336702B2 (en) 2010-11-29 2016-10-06 Novelmed Therapeutics, Inc. Neoantibodies for diagnosing tissue injury
AU2014209350B8 (en) * 2013-01-23 2019-04-18 Department Of Veterans Affairs (Us) Targeting constructs based on natural antibodies and uses thereof
AU2014348683B2 (en) * 2013-11-18 2020-11-05 Rubius Therapeutics, Inc. Synthetic membrane-receiver complexes
US10035848B2 (en) 2014-01-08 2018-07-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody targeting cell surface deposited complement protein C3d and use thereof
ES2865825T3 (es) * 2014-04-01 2021-10-18 Rubius Therapeutics Inc Procedimientos y composiciones para inmunomodulación
CN106687123A (zh) * 2014-06-05 2017-05-17 科罗拉多州大学评议会 Map44多肽和基于天然抗体的构建体及其用途
CR20170383A (es) * 2015-01-23 2017-11-22 Sanofi Sa Anticuerpos anti-cd3, anticuerpos anti-cd-123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040180046A1 (en) * 2000-04-26 2004-09-16 Jeff Himawan Bispecific molecules and uses thereof
US20130078245A1 (en) * 2010-06-22 2013-03-28 The Regents Of The University Of Colorado, A Body Corporate ANTIBODIES TO THE C3d FRAGMENT OF COMPLEMENT COMPONENT 3
WO2014028865A1 (en) * 2012-08-17 2014-02-20 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for detecting complement activation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Fridkis-Hareli, M. et al., Blood, (2011-10-27), vol. 118, no. 17, pages 4705 - 4713, doi: 10.1182/blood-2011-06-359646. *

Also Published As

Publication number Publication date
JP2024059791A (ja) 2024-05-01
KR102762828B1 (ko) 2025-02-05
KR20210148076A (ko) 2021-12-07
IL283841A (en) 2021-07-29
AU2024201109A1 (en) 2024-03-14
US20240301043A1 (en) 2024-09-12
CN113660944A (zh) 2021-11-16
MY209796A (en) 2025-08-05
CA3123004A1 (en) 2020-06-18
MA54468A (fr) 2022-04-13
KR20250021629A (ko) 2025-02-13
SG11202106073QA (en) 2021-07-29
EP3893916A2 (en) 2021-10-20
EP3893916A4 (en) 2023-03-29
WO2020123662A2 (en) 2020-06-18
JP2022512234A (ja) 2022-02-02
JP7444886B2 (ja) 2024-03-06
MX2021006930A (es) 2021-11-17
WO2020123662A3 (en) 2020-07-23
AU2019398214B2 (en) 2023-11-23
AU2019398214A1 (en) 2021-07-01
JP7811315B2 (ja) 2026-02-05
PH12021551398A1 (en) 2022-11-07
JP2026053563A (ja) 2026-03-25

Similar Documents

Publication Publication Date Title
US11879008B2 (en) Methods of treating complement mediated diseases with fusion protein constructs comprising anti-C3d antibody and a complement modulator
AU2019398214B2 (en) Fusion protein constructs for complement associated disease
JP6608702B2 (ja) 補体関連疾患の予防及び治療のためのｃ５抗体及び方法
TW201843180A (zh) 具有肌營養不良蛋白聚糖和層黏連結蛋白－２特異性的多特異性結合分子
AU2019397614B2 (en) Antibodies to human complement factor C2b and methods of use
KR20190003951A (ko) 항-보체 인자 bb 항체 및 이의 용도
EP3288974B1 (en) Type iii secretion system targeting molecules
JP2025529954A (ja) 抗ヒト補体ｃ５抗体およびその融合タンパク質
US20250243266A1 (en) Anti-c3 antibodies and antigen-binding fragments thereof and their uses for treating eye or ocular diseases
CA3123004C (en) Fusion protein constructs for complement associated disease
RU2824402C2 (ru) Конструкции слитого белка для заболевания, связанного с комплементом
KR20250102072A (ko) 보체-억제 하이브리드 단백질 돌연변이체 및 이의 항체와의 융합 단백질
TW202528343A (zh) 抗c2結合劑及其結合物
WO2025260123A1 (en) Anti-c2 antibodies and uses thereof
HK40121588A (zh) 针对人补体因子c2b的抗体及使用方法
HK40050349B (zh) 针对人补体因子c2b的抗体及使用方法

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 20 DEC 2023

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 20 DEC 2023

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: AKEBIA THERAPEUTICS, INC.

Free format text: FORMER OWNER(S): Q32 BIO INC.